ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry Healthcare Cash Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FCAHHYPOTHETICAL MODEL
Since ’99
−52%
Expense Ratio
0.45%
placeholder
Holdings
100
cap-weighted
Inception
Dec 2019
placeholder
Full Sharpe
0.03
Ann. Return (LS)
0.9%
Ann. Volatility
26.7%
Max Drawdown
-92.2%
Test Sharpe ’19–26
-0.11
Test FF5 α (ann.)
5.8%
vs Fama-French 5
Test FF5 α t-stat
0.94
not significant
Monthly turnover
14%
of the long leg, per rebalance
Cumulative return (LS)
-52%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.28
what this fund holds
Long leg ann. return
8.7%
buyable, long-only
Long-short Sharpe
0.03
requires shorting
Bottom bucket ann. return
7.7%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

100 of 100 · 100.0% of book
TickerCompanySectorMarket capWeight
1ONC
BEONE MEDICINES LTDHealthcare$34.68B
16.35%
2GH
GUARDANT HEALTH INCHealthcare$20.67B
9.74%
3BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
7.51%
4OSCR
OSCAR HEALTH INCHealthcare$8.77B
4.14%
5IMVT
IMMUNOVANT INCHealthcare$8.27B
3.90%
6LQDA
LIQUIDIA CORPHealthcare$7.11B
3.35%
7SRRK
SCHOLAR ROCK HOLDING CORPHealthcare$6.33B
2.99%
8BLLN
BILLIONTOONE INCHealthcare$5.99B
2.83%
9DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
2.72%
10TXG
10X GENOMICS INCHealthcare$5.55B
2.62%
11DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
2.28%
12CAI
CARIS LIFE SCIENCES INCHealthcare$4.66B
2.20%
13ALHC
ALIGNMENT HEALTHCARE INCHealthcare$4.26B
2.01%
14DYN
DYNE THERAPEUTICS INCHealthcare$3.92B
1.85%
15CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
1.82%
16PBLS
PARABILIS MEDICINES INCHealthcare$3.51B
1.65%
17KOD
KODIAK SCIENCES INCHealthcare$2.67B
1.26%
18IMNM
IMMUNOME INCHealthcare$2.53B
1.19%
19SLS
SELLAS LIFE SCIENCES GROUP INCHealthcare$2.45B
1.16%
20BHVN
BIOHAVEN LTDHealthcare$2.32B
1.10%
21PVLA
PALVELLA THERAPEUTICS INCHealthcare$2.26B
1.06%
22PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.94%
23AMLX
AMYLYX PHARMACEUTICALS INCHealthcare$1.97B
0.93%
24OCUL
OCULAR THERAPEUTIX INCHealthcare$1.96B
0.93%
25DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
0.91%
26ZBIO
ZENAS BIOPHARMA INCHealthcare$1.86B
0.88%
27BCAX
BICARA THERAPEUTICS INCHealthcare$1.82B
0.86%
28ZYME
ZYMEWORKS INCHealthcare$1.77B
0.83%
29BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.82%
30TSHA
TAYSHA GENE THERAPIES INCHealthcare$1.71B
0.81%
31ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.80%
32CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
0.79%
33MAZE
MAZE THERAPEUTICS INCHealthcare$1.56B
0.73%
34MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.68%
35OMDA
OMADA HEALTH INCHealthcare$1.41B
0.66%
36AKTS
AKTIS ONCOLOGY INCHealthcare$1.33B
0.63%
37INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.60%
38AVLN
AVALYN PHARMA INCHealthcare$1.25B
0.59%
39IRMD
IRADIMED CORPHealthcare$1.24B
0.58%
40WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
0.53%
41PRCT
PROCEPT BIOROBOTICS CORPHealthcare$1.09B
0.52%
42BIOA
BIOAGE LABS INCHealthcare$1.01B
0.48%
43FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.47%
44ANRO
ALTO NEUROSCIENCE INCHealthcare$967M
0.46%
45ANNX
ANNEXON INCHealthcare$950M
0.45%
46LBRX
LB PHARMACEUTICALS INCHealthcare$901M
0.42%
47TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.41%
48PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.41%
49REPL
REPLIMUNE GROUP INCHealthcare$859M
0.40%
50SLDB
SOLID BIOSCIENCES INCHealthcare$859M
0.40%
51AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.39%
52CADL
CANDEL THERAPEUTICS INCHealthcare$746M
0.35%
53AURA
AURA BIOSCIENCES INCHealthcare$723M
0.34%
54SGP
SPYGLASS PHARMA INCHealthcare$661M
0.31%
55ACHV
ACHIEVE LIFE SCIENCES INCHealthcare$644M
0.30%
56TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.29%
57NGNE
NEUROGENE INCHealthcare$590M
0.28%
58STTK
SHATTUCK LABS INCHealthcare$577M
0.27%
59IMMX
IMMIX BIOPHARMA INCHealthcare$558M
0.26%
60VSTM
VERASTEM INCHealthcare$530M
0.25%
61ZURA
ZURA BIO LTDHealthcare$518M
0.24%
62NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.24%
63PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.21%
64BNTC
BENITEC BIOPHARMA INCHealthcare$439M
0.21%
65TENX
TENAX THERAPEUTICS INCHealthcare$420M
0.20%
66CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.19%
67MOBI
MOBIA MEDICAL INCHealthcare$404M
0.19%
68FENC
FENNEC PHARMACEUTICALS INCHealthcare$365M
0.17%
69CV
CAPSOVISION INCHealthcare$335M
0.16%
70CARL
CARLSMED INCHealthcare$317M
0.15%
71SGHT
SIGHT SCIENCES INCHealthcare$274M
0.13%
72TTRX
TURN THERAPEUTICS INCHealthcare$272M
0.13%
73CNXU
CONEXEU SCIENCES INCHealthcare$263M
0.12%
74QTTB
Q32 BIO INCHealthcare$255M
0.12%
75SRZN
SURROZEN INCHealthcare$255M
0.12%
76GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.11%
77UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.10%
78KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.10%
79KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.10%
80RNA
ATRIUM THERAPEUTICS INCHealthcare$208M
0.10%
81IMUX
IMMUNIC INCHealthcare$207M
0.10%
82DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.10%
83AMWL
AMERICAN WELL CORPHealthcare$199M
0.09%
84TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.09%
85ACOG
ALPHA COGNITION INCHealthcare$185M
0.09%
86ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.08%
87OWLT
OWLET INCHealthcare$162M
0.08%
88UNCY
UNICYCIVE THERAPEUTICS INCHealthcare$144M
0.07%
89PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.06%
90VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.06%
91AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.06%
92CUE
CUE BIOPHARMA INCHealthcare$126M
0.06%
93SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.06%
94VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.05%
95RLYB
RALLYBIO CORPHealthcare$87M
0.04%
96NRXS
NEURAXIS INCHealthcare$84M
0.04%
97IMA
IMAGENEBIO INCHealthcare$61M
0.03%
98EDSA
EDESA BIOTECH INCHealthcare$59M
0.03%
99INKT
MINK THERAPEUTICS INCHealthcare$53M
0.03%
100XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.03%

Full long-leg book as of July 2026 · cap-weighted · total market cap $212.14B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

100 classified
Value
Blend
Growth
Large
Mid
Small
6%2
7%3
36%8
4%6
8%10
9%10
5%30
3%12
1%8

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 75% toward Large, 70% toward Growth. +21% unclassified (11 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt75% → Large
SmallLarge
Value ↔ growth tilt70% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 100 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 100 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
2.3 (95% CI 1.5-3.0)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
22.6%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
2.34x
over
parametric
2.07x
over
cornish fisher
2.18x
over

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2012
Before publication (pre-2012)
0.12
Sharpe · 3.5% p.a.
January 1999December 2012 · 168 mo
Since publication
-0.07
Sharpe · -1.7% p.a.
January 2013July 2026 · 163 mo
Change in Sharpe−0.19the return reversed sign — the published edge now runs the other way

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
54%
14 of 26 3-year windows made money
Worst window
-0.98
Sharpe, January 2021 – December 2023
January 1999July 2026
Median Sharpe
0.03
Dispersion
0.40
Best window
0.95

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.46.1%22.5%
3 yearsp.a.15.6%6.5%
5 yearsp.a.-2.8%-7.4%
10 yearsp.a.3.1%-3.9%
Since inceptionp.a.3.8%-2.7%
Calendar years
YearLong legLong-short
20267 mo11.5%9.0%
202542.8%21.6%
2024-6.6%-15.5%
202318.7%17.3%
2022-32.1%-22.9%
2021-45.9%-57.9%
202044.1%33.6%
201934.5%13.0%
2018-15.8%-18.8%
201726.7%12.9%
2016-23.1%-11.1%
20152.3%-2.6%
201434.3%12.0%
201339.3%-8.5%
201230.4%12.8%
2011-0.6%-7.0%
201010.3%3.4%
200917.5%-5.0%
2008-27.1%-0.3%
2007-4.8%-8.7%
200610.3%0.3%
20055.3%4.2%
2004-4.5%4.1%
200352.2%28.4%
2002-41.7%-28.7%
2001-26.1%-26.0%
2000-5.6%-38.5%
199977.6%113.5%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FCAH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-12-03 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$212.14B

Methodology

The Foundry Healthcare Cash Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Cash signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.